NEW YORK and AMSTERDAM, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Atai Beckley N.V. (NASDAQ: ATAI) (“AtaiBeckley” or “Company”),…
atai Life Sciences (NASDAQ:ATAI, ETR:9VC) announced that its previously annoucned strategic combination with Beckley Psytech has been completed, forming a...…
atai Life Sciences (NASDAQ:ATAI, ETR:9VC) announced the completion of a $149.5 million public offering of approximately 27 million common shares,…
atai Life Sciences (NASDAQ:ATAI, ETR:9VC) announced the completion of a $149.5 million public offering of approximately 27 million common shares,…
atai Life Sciences (ATAI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade…
atai Life Sciences (NASDAQ:ATAI, ETR:9VC) announced that it has priced its registered underwritten offering of 23,725,000 company common shares at $5.48 per...…
atai Life Sciences (NASDAQ:ATAI, ETR:9VC) and Beckley Psytech announced that the US Food and Drug Administration (FDA) has granted Breakthrough…
atai Life Sciences (NASDAQ:ATAI, ETR:9VC) chief scientific officer Glenn Short spoke with Proactive about the company’s recent NIH grant and its innovative...…
…
Atai Life Sciences stock hits 52-week high at $5.35…
Shares in atai Life Sciences (NASDAQ:ATAI, ETR:9VC) rose 10% on Tuesday after the company and its UK partner Beckley Psytech reported…
atai Life Sciences (NASDAQ:ATAI, ETR:9VC) and Beckley Psytech said Tuesday that their experimental nasal spray for depression showed promising results…
5-year UG3/UH3 grant will fund the optimization and early-stage development of atai’s novel 5-HT2A/2C receptor agonists with non-hallucinogenic potential for…
atai Life Sciences (NASDAQ:ATAI, ETR:9VC) announced that it has been awarded a grant of up to $11.4 million from the…
…
…
…
atai Life Sciences (NASDAQ:ATAI, ETR:9VC) said on Friday that its platform company, Recognify Life Sciences, reported top-line results from a…
…
ATAI Life Sciences stock falls after Recognify’s CIAS drug misses endpoint…
atai Life Sciences (NASDAQ:ATAI, ETR:9VC) is gaining momentum in the psychedelics space, with Jefferies analysts highlighting the company’s potential to...…
atai Life Sciences (NASDAQ:ATAI, ETR:9VC) is gaining momentum in the psychedelics space, with Jefferies analysts highlighting the company’s potential to...…
atai Life Sciences (ATAI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade…
Sales of Johnson & Johnson (NYSE:JNJ)’s esketamine nasal spray Spravato grew sequentially in the second quarter, marking a positive sign for…
Here is how atai Life Sciences N.V. (ATAI) and Idexx Laboratories (IDXX) have performed compared to their sector so far…
…
Atai Life Sciences (NASDAQ:ATAI, ETR:9VC) announced positive topline results from its Phase 2b clinical study in patients with treatment-resistant...…
atai Life Sciences (NASDAQ:ATAI, ETR:9VC) remains a ‘Buy’ for analysts at Jefferies, who continue to see significant upside ahead for…
…
Does atai Life Sciences N.V. (ATAI) have what it takes to be a top stock pick for momentum investors? Lets…
atai Life Sciences (NASDAQ:ATAI, ETR:9VC) stock is poised to move higher following its planned merger with Beckley Psytech, as the…
ATAI Life Sciences stock soars on Beckley Psytech merger deal…
atai Life Sciences (NASDAQ:ATAI, ETR:9VC) shares soared before Monday’s opening bell after it announced it has inked a definitive agreement…
atai Life Sciences (NASDAQ:ATAI, ETR:9VC) announced it has inked a definitive agreement to merge with Beckley Psytech, a private clinical-stage...…
atai Life Sciences (NASDAQ:ATAI, ETR:9VC) CEO and co-founder Dr Srinivas Rao talked with Proactive about the company’s clinical development progress…
Does atai Life Sciences N.V. (ATAI) have what it takes to be a top stock pick for momentum investors? Lets…
atai Life Sciences (NASDAQ:ATAI, ETR:9VC) could see its stock more than double following the release of key trial data later…
atai Life Sciences (NASDAQ:ATAI, ETR:9VC) could see its stock more than double following the release of key trial data later…
atai Life Sciences (NASDAQ:ATAI, ETR:9VC) announced positive topline data from Part 2 of Beckley Psytech’s Phase 2a study of BPL-003, an…
atai Life Sciences (NASDAQ:ATAI, ETR:9VC) has announced positive topline data from Part 2 of Beckley Psytech’s Phase 2a study of…
atai Life Sciences (NASDAQ:ATAI, ETR:9VC)’ stock is poised to climb significantly, driven by a series of clinical catalysts this year…
atai Life Sciences (NASDAQ:ATAI, ETR:9VC) has kicked off 2025 with strong momentum across its clinical pipeline ahead of expected key…
atai Life Sciences (NASDAQ:ATAI, ETR:9VC) announced that it has dosed the first patient in its Phase 2 clinical trial of…
atai Life Sciences (NASDAQ:ATAI, ETR:9VC) CEO Dr Srinivas Rao talked with Proactive about the companys upcoming clinical milestones and strategic focus…
atai Life Sciences (NASDAQ:ATAI, ETR:9VC) is entering a pivotal period with data from several key trials expected in 2025 and…
atai Life Sciences (NASDAQ:ATAI, ETR:9VC) is entering a pivotal period with data from several key trials expected in 2025 and…
atai Life Sciences (NASDAQ:ATAI, ETR:9VC) said it saw significant progress in 2024 with key advancements in its clinical trials as…
atai Life Sciences (NASDAQ:ATAI, ETR:9VC) announced that the first patient has been dosed in its Phase 2 Elumina trial of…
atai Life Sciences (NASDAQ:ATAI, ETR:9VC) announced that patient enrollment has been completed in Beckley Psytech’s Phase 2b trial evaluating BPL-003…
atai Life Sciences (NASDAQ:ATAI, ETR:9VC) announced that it has closed is public offering of shares and the underwriter’s option to…